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Abstract
Turner syndrome (TS) is characterized by a set of clinical conditions, including autoimmune/inflammatory diseases
and infectious conditions, that can compromise a patient’s quality of life. Here we assessed polymorphisms in
CTLA-4 +49A/G (rs231775), PTPN22 +1858G/A (rs2476601), and MBL2 -550 (H/L) (rs11003125), -221(X/Y)
(rs7096206) and exon 1 (A/O) in women from northeastern Brazil to determine whether polymorphisms within these
key immune response genes confer differential susceptibility to clinical conditions in TS. A case-control genetic asso-
ciation study was performed, including 86 female TS patients and 179 healthy women. An association was observed
for the A/G genotype of CTLA-4 +49A/G in TS patients (p=0.043, odds ratio [OR]=0.54). In addition, an association
between the CTLA-4 G/G genotype and obesity was detected in TS patients (p=0.02, OR=6.04). Regarding, the
-550(H/L) polymorphism in the MBL2 promoter, the frequency of the H/L genotype was significantly higher in the TS
group than healthy controls (p=0.01, OR=1.96). The H/H genotype indicated a protective effect in TS patients
(p=0.01, OR=0.23). No differences were observed in the distribution of -221(X/Y), MBL2 exon 1 variants, and
PTPN22 +1858G/A in any assessed groups. CTLA-4 variants are potentially involved in obesity in this cohort of TS
patients from northeastern Brazil.
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Introduction
Turner syndrome (TS) is one of the most common
chromosomal abnormalities in humans and is characterized
by the presence of one X chromosome and total or partial
loss of the second sex chromosome. TS is estimated to af-
fect 1 in every 2500 live female births (Stochholm et al.,
2006). Individuals with TS exhibit a set of phenotypic fea-
tures, including short stature and gonadal dysgenesis. Other
clinical conditions, such as osteoporosis, dyslipidemia,
obesity and congenital malformations are also observed
(Ostberg et al., 2005; Carvalho et al., 2010; Bispo et al.,
2013; Ríos Orbañanos et al., 2015).
Some studies have reported increased levels of auto-
antibodies (anti-thyroid peroxidase and anti-glutamic-acid-
decarboxylase) in TS patients and an increased risk of
developing a range of autoimmune diseases, such as Hashi-
moto’s thyroiditis, type I diabetes mellitus, celiac disease,
Crohn’s disease, ulcerative colitis, juvenile rheumatoid ar-
thritis, Addison’s disease, autoimmune hepatitis, psoriasis,
vitiligo, and alopecia (Mortensen et al., 2009; Bianco et al.,
2010; Jørgensen et al., 2010; Bakalov et al., 2012). In addi-
tion, ovarian insufficiency and absence of a second normal
X chromosome are linked to an increased risk of autoim-
mune disorders in these patients. However, the underlying
pathophysiological mechanisms related to the immune un-
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balance remain to be fully elucidated (Mortensen et al.,
2009; Bakalov et al., 2012).
A wide variety of autoimmune/inflammatory dis-
eases and infectious conditions have been associated with a
set of genes related to immune regulation, including the ty-
rosine-protein phosphatase non-receptor type 22 gene
(PTPN22), cytotoxic T-lymphocyte-associated protein 4
gene (CTLA4), and mannose-binding lectin (MBL2) (Bot-
tini et al., 2004; Bevilacqua Filho et al., 2012; Katkam et
al., 2015). Polymorphisms within these three genes have
been analyzed due to their importance in immune balance
and homeostasis within the body. Even though a body of
evidence indicates immune deregulation processes in TS,
only PTPN22 rs2476601 has been assessed in Brazilian TS
patients from São Paulo (Southeast region) (Bianco et al.,
2010). Furthermore, studies evaluating the role of MBL2
and CTLA-4 polymorphisms in TS and its association with
clinical features are lacking.
To understand the role of these key genes in immune
misbalance and its consequences, we assessed whether
PTPN22, CTLA-4, and MBL2 polymorphisms confer sus-
ceptibility to autoimmune conditions or other inflamma-
tion-related features in TS patients from Northeast Brazil.
Materials and Methods
Patients and controls
This study included 86 patients with cytogenetic di-
agnosis of TS, who attended at Medical Genetics Service of
Institute of Integral Medicine Professor Fernando Figueira
and at Pediatric Endocrinology Service of Clinical Hospital
of Federal University of Pernambuco. It was proposed as a
pilot study. At time of TS diagnosis, patients mean age was
11.48 years old (SD  7.52 years old), ranging from 0.1 to
33 years. Clinical data shown in the Table 1 were obtained
from medical records of each patient. The control group in-
cluded 179 healthy women from the same geographical re-
gion. Their mean age was 34.62 years old (SD  13.4 years
old), ranging from 8 to 72 years. Exclusion criteria for the
control group included an individuals’ history of autoim-
mune and inflammatory chronic disease, also in close rela-
tives such as parents. All individuals (or their legal
responsible) included in this research signed an informed
consent term, which followed the Declaration of Helsinki
guidelines and presented the approval number from local
Ethics Committee (Record: CEP/IMIP N° 802/06;
CEP/CCS/UFPE N° 493/11).
Karyotyping
Clinical diagnosis of 86 TS patients was confirmed
by chromosome analysis in peripheral blood leucocyte.
Karyotypes found were as follows: 45,X (n=47, 54.65%);
45,X/46,X,i(Xq) (n=15, 17.44%); 46,X,i(Xq) (n=4,
4.65%); 45,X/46,XY (n=4, 4.65%); 45,X/46,X,r(X) (n=3,
3.49); other chromosomal constitutions summed 13 indi-
viduals (15.12%).
DNA extraction and genotyping
Genomic DNA was extracted from whole blood using
IllustraTM Blood GenomicPrep Mini Spin Kit (GE
Healthcare) according to manufacturer’s instructions.
SNPs selection was based on minimum allele frequency
(MAF) of 10% and/or SNP consequence/function upon
gene action. A total of five SNPs were selected distributed
as follows PTPN22 +1858G/A (rs2476601) at codon 620,
CTLA-4 +49A/G (rs231775) within codon 17 in the first
exon and MBL2 promoter region -550(H/L) (rs11003125),
-221(X/Y) (rs7096206). Genotyping was performed using
TaqMan SNP genotyping assays and Taqman Universal
Master Mix (Applied Biosystems®, CA) according to
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Table 1 - Clinical characterization of all Turner syndrome patients en-
rolled in our study.
Clinical characteristics N
Short stature 69
Skeletal abnormalities 72a
Osteopenia/osteoporosis 4
Sexual infantilism 100b
Primary amenorrhea 31
Obesity 9
Dyslipidemia 5
Autoimmune thyroid disease 11
Alopecia 2
Inflammatory diseases 9
Infectious diseases 6
Neurological disease 23
Cardiovascular disease 17
Renal malformations 10
Skin diseases 17
Edema 35
Mammary hypertelorism 22
Hearing impairment 7
Ear malformations 21
Muscle hypotonia 3
Arched palate 7
Nails malformations 33
Eyes anatomic alterations 13
Visual impairment 2
Short and webbed neck 35
Low posterior hairline 21
Skin redundancy in the neck 18
aMain clinical conditions are cubitus valgus, pectus scavatum and genu
valgus;
bAbsent mammary development, absent axillary and pubic hair, hypo-
plastic uterus and absent ovaries;
manufacturer instructions. SNP assessment within MBL2
exon 1 (A/O) was performed using SYBR Green (Qiagen,
Hilden, Germany) as previously described (Hladnik et al.,
2002). All Sybr Green endpoint PCRs were performed, in-
cluding all three possible genotypes as positive controls, in
a Rotor-Gene 6000 TM apparatus (Corbett Research Mort-
lake, Sydney, Australia). Ten randomly chosen MBL2
genotyped samples were sequenced in order to dou-
ble-check the Melting Temperature assay (MTA) results.
We found 100% concordance between sequenced samples
and the MTA results.
Statistical analysis
Statistical analyses were carried out using SNPStats
available at http://bioinfo.iconcologia.net/SNPstats_web
and R software (https://www.r-project.org/). Hardy–Wein-
berg equilibrium was tested for each polymorphism by
comparing observed with expected frequencies using
chi-square (2) tests. Differences in allele and genotype
frequencies from each studied polymorphism in patients
and controls were assessed using 2 or Fisher’s exact test.
Odds Ratio (OR) and 95% Confidence Intervals (CI) were
also calculated and a p-value < 0.05 was considered statisti-
cally significant. Combined alleles for the PTPN22 and
CTLA-4 genes, haplotypes for the MBL2 gene and a possi-
ble association of these combined alleles and haplotype
with clinical conditions in TS patients were also assessed.
Combined genotypes for the MBL2 gene were assessed by
Arlequin version 3.1 software (Excoffier et al., 2005).
Fisher’s exact test was performed to evaluate difference be-
tween combined genotypes in case-control and associations
with clinical data in TS group. We compared genotype and
allele distribution for all SNPs assessed in this study in TS
patients and control group. Posteriorly, we evaluated a pos-
sible association of all polymorphic variants with differen-
tial presence of autoimmune diseases such as autoimmune
thyroid disease and alopecia and other clinical features as
follows: obesity, dyslipidemia, inflammatory and infec-
tious conditions in TS patients. Post-hoc (goodness of fit 2
tests) power analysis was performed with the G* Power
software (version 3.1.9.2, available at
http://www.gpower.hhu.de/), with  error probability of
0.05
Results
PTPN22 and CTLA-4 gene polymorphisms
The allele and genotype distributions of PTPN22
rs2476601 (G > A) and CTLA-4 rs231775 (A > G) among
TS patients and healthy controls are summarized in Table 2.
Conformity to Hardy-Weinberg equilibrium (HWE; p >
0.05) was observed in both SNP distributions, and no sig-
nificant differences were found in the allele and genotype
frequencies of these variants in both groups (Table 2).
We did not detect the homozygous A/A genotype of
PTPN22 rs2476601 (G > A) in any of the studied groups. A
lower frequency of the A allele and G/A genotype was ob-
served in both TS patients and controls (Table 2). No signif-
icant association was identified between the assessed SNPs
and the presence of any clinical conditions in women with
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Table 2 - Genotype and allele distribution of PTPN22 and CTLA-4 gene polymorphisms in TS and controls group.
Polymorphism Patients N (%) Controls N (%) Odds ratio (95% CI) p-value
PTPN22 rs2476601
Allele 172 358
G 170 (99%) 345 (96%) 1.00
A 2 (1%) 13 (4%) 0.31 (0.03-1.40) 0.16
Genotype 86 179
GG 84 (97.7%) 166 (92.7%) 1.00
GA 2 (2.3%) 13 (7.3%) 0.30 (0.03-1.39) 0.15
AA 0 (0.0%) 0 (0.0%) 0 (0 inf) 1.00
CTLA-4 rs231775
Allele 172 340
A 114 (66%) 203 (60%) 1.00
G 58 (34%) 137 (40%) 0.75 (0.50-1.12) 0.17
Genotype 86 170
AA 41 (47.7%) 59 (34.7%) 1.00
AG 32 (37.2%) 85 (50%) 0.54 (0.29 - 0.99) 0.043*
GG 13 (15.1%) 26 (15.3%) 0.72 (0.30-1.66) 0.44
TS = Turner syndrome; CI = confidence interval; p < 0.05 was considered statistically significant.
*Significant difference using Fisher’s exact test.
TS (p > 0.05; Fisher’s exact test) (Table S1). The power
was 80.7% (-error = 5% confidence) to detect a medium
effect size (w=0.3) for PTPN22 genotypes in both patients
and controls.
Concerning CTLA-4 rs231775, significantly different
distributions of genotype frequencies were observed in TS
patients compared to the control group. An association was
detected for the A/G genotype (p=0.043, OR=0.54), indi-
cating a differential distribution for this SNP in TS patients.
The power was 99% (-error = 5% confidence) to detect a
medium effect size (w=0.3) for CTLA4 genotypes compar-
ing patients and controls. Furthermore, when assessing the
clinical features of TS and the allele and genotype distribu-
tion, we detected an association between the CTLA-4 allele
(recessive model: A/A—A/G vs. G/G) and obesity in TS
patients (p=0.02, 95% CI 1.37-26.75, OR=6.04) (Table 3,
Table S2).
Combined alleles for PTPN22 and CTLA-4 genes
The combined alleles of PTPN22 and CTLA-4 and
frequencies for both groups are given in Table 5. No signifi-
cant differences were observed. Furthermore, no signifi-
cant association was established between the combined
alleles and clinical status of TS patients (Table S3).
MBL2 gene polymorphisms
The MBL2 genotype and allele distributions in TS pa-
tients and controls are given in Table 4. All allelic and
genotypic frequencies of MBL2 polymorphisms were in
HWE in the TS and control groups, except for rs11003125
(-550 H/L) in the TS group (p < 0.05). The H/L genotype
frequency was significantly higher in TS patients than con-
trols (overdominant model: H/L vs. L/L—H/H: p=0.01,
OR=1.96, 95% CI 1.11-3.50). Furthermore, the H/H geno-
type indicated a protective effect in TS patients compared
to healthy controls (recessive model: H/H vs. L/L—H/L:
p=0.01, OR=0.23, 95% CI 0.04-0.83). Again, this result
cannot be fully explained due to an absence of HWE in this
specific group. The power was 99.9% (5% confidence) to
detect a medium effect size (w=0.3) for -550 MBL2 geno-
types in both groups.
Regarding MBL2 rs7096206 (-221 X/Y), no differ-
ences in allele or genotype frequencies were observed be-
tween TS patients and controls. The power was 30.5% (5%
confidence) to detect a medium effect size (w=0.3) for -221
MBL2 genotypes when comparing patients and controls.
Furthermore, no significant differences were observed in
the genotype and allele frequencies of exon 1 variants be-
tween TS patients and controls. The power was 91.2% (5%
confidence) to detect a medium effect size (w=0.3) for exon
1 MBL2 genotypes when comparing TS patients and con-
trols. In patients with TS, no SNP in the MBL2 gene or
promotor region was associated with clinical characteris-
tics (Table S4).
Haplotypes and combined genotypes of MBL2 gene
-550, -221, and exon 1 variants
The frequencies of haplotypes and combined geno-
types originating from linkage disequilibrium between the
MBL2 -550 and -221 promoter region and exon 1 poly-
morphisms are given in Table 5. Haplotypes were com-
bined in different groups; haplotypes associated with high
expression of MBL (LYA, HYA), low production of MBL
(LXA), and deficient expression of MBL (LYO, HYO). No
significant differences were found in haplotype frequencies
between the analyzed groups. Furthermore, no significant
association was established among haplotypes and the clin-
ical data of TS patients (Table S5).
Genotypes were classified as high (HYA/HYA,
HYA/LYA, and LYA/LYA); low (LXA/LXA, LYA/LXA,
HYA/LXA, HYA/HYO, HYA/LYO, and LYA/LYO); and
deficient producers of MBL (HYO/HYO, HYO/LXA,
HYO/LYO, LYO/LXA, and LYO/LYO). Significant dif-
ferences were not found between the evaluated groups.
Moreover, no significant difference was observed among
combined genotypes and the clinical data of TS patients
(Table S6).
Discussion
To date, only a few assays have been performed in-
volving genes linked to innate and adaptive immunity in
patients with TS, even though the immune response seems
impaired in these patients (Bianco et al., 2010, 2012).
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Table 3 - Genotype distribution of CTLA-4 gene polymorphisms in TS group.
Model Polymorphism Obesity N (%) Non-obesity N (%) Odds ratio (95% CI) p-value
Recessive CTLA-4
rs231775
Genotype
AA- AG 5 (55.6%) 68 (88.3%) 1.00
GG 4 (44.4%) 9 (11.7%) 6.04 (1.37 - 26.75) 0.023
CI = confidence interval; p < 0.05 was considered statistically significant.
We included PTPN22 in our analyses due to its im-
portance in the host immune system; this gene encodes
LYP, an important negative regulator of T cell activation
(Bottini et al., 2004). Our results indicate an absence of an
association between the selected PTPN22 SNP and auto-
immunity, inflammatory, and infectious conditions in TS
women.
Our results differ from Bianco et al. (2010), who
found an association between the same SNP (PTPN22
rs2476601) and the development of autoimmune diseases
in TS in another cohort from Southeast Brazil. The fre-
quency of the A allele in women with TS (1.1%) and
healthy controls (3.6%), as well as the heterozygote geno-
type in both groups (2.3% and 7.3%, respectively), was
lower in our study than that of Bianco et al. (2010). In their
study, the frequency of the A allele and heterozygote geno-
type were 18.3% and 28.2% in the TS group, and 9.2% and
16.1% in controls, respectively. A disease-associated
homozygote genotype was present in 4.2% of patients and
1.1% of controls.
This difference between studies could be due to varia-
tion in allele frequencies of some disease-associated SNPs
in different ethnic groups (Mori et al., 2005), because the
Brazilian population exhibits variety in allele distribution.
Geographic distributions in Brazil exhibit ethnic dispari-
ties, mainly due to the genetic burden of heterogeneous col-
onization sources (Pena et al., 2009; Coelho et al., 2015).
We also evaluated PTPN22 rs2476601 (G > A) and
other clinical features in TS patients, such as obesity, as
well as dyslipidemia, given its role in modulating inflam-
matory conditions. As obesity is a disease characterized by
chronic mild inflammation, the concentration of acute
phase proteins and cytokines associated with inflammation
are higher in obese individuals compared to normal weight
individuals (Trayhurn, 2007). However, our analysis did
not indicate an association between these clinical manifes-
tations in the TS group, which is similar to a previous study
by Salinas-Santander et al. (2016), in which PTPN22
+1858G/A was not associated with differential susceptibil-
ity to overweight and the development of obesity in adoles-
cents.
The CTLA-4 +49A/G polymorphism at exon 1 is in-
volved in the negative regulation of T cells. Our assay
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Table 4 - Genotype and allele distribution of MBL2 gene polymorphisms in TS and controls group.
Inheritance Model Polymorphism Patients N (%) Controls N (%) Odds ratio (95% CI) p-value
MBL2 rs11003125
Allele 172 300
L 116 (67.0%) 198 (66.0%) 1.00
H 56 (33.0%) 102 (34.0%) 0.93 (0.61- 1.42) 0.76
Recessive Genotype 86 150
L/L—H/L 83 (96.5%) 130 (86.7%) 1.00
H/H 3 (3.5%) 20 (13.3%) 0.23 (0.04-0.83) 0.01*
Overdominant Genotype 86 150
L/L—H/H 36 (41.9%) 88 (58.7%) 1.00
H/L 50 (58.1%) 62 (41.3%) 1.96 (1.11-3.50) 0.01*
MBL2 rs7096206
Allele 172 300
Y 147 (85%) 256 (85%) 1.00
X 25 (15%) 44 (15%) 0.98(0.55-1.73) 1.0
Recessive Genotype 86 150
Y/Y—X/Y 84 (97.7%) 144 (96.0%) 1.00
X/X 2 (2.3%) 6 (4.0%) 0.57(0.05-3.29) 0.7
MBL2 Exon 1
Allele 126 300
A 98 (78%) 253 (84%) 1.00
O 28 (22%) 47 (16%) 1.53(0.87-2.66) 0.12
Dominant Genotype 63 150
A/A 39 (61.9%) 108 (72%) 1.00
A/O - O/O 24 (38.1%) 42 (28%) 1.57(0.80-3.06) 0.14
TS = Turner syndrome; CI = confidence interval; p < 0.05 was considered statistically significant.
*Significant difference using Fisher’s exact test.
showed an association between the rs231775 G/G genotype
and obesity in the TS group (p=0.02).
The presence of the CTLA-4 +49A/G variant has been
associated with different diseases, and G/G individuals
may possess CTLA-4 protein with a weak suppression
function compared to individuals with the A/A genotype
(Chistiakov and Turakulov, 2003). Therefore, increased
T-cell activation due to this reduced inhibitory signal to T
cells would be associated with the pathogenesis of several
autoimmune/inflammatory diseases, including obesity, as
observed with TS patients in the present study. The adipo-
cytes of obese individuals with TS express fewer anti-
inflammatory elements and high amounts of pro-
inflammatory factors, leading to a misplaced response in
immune cells (Ostberg et al., 2005; Bakalov et al., 2012).
MBL2 polymorphisms and their influence on serum
protein levels have been evaluated extensively and found to
be associated with recurrent and severe infections (Sumiya
et al., 1991; Summerfield et al., 1995), such as tuberculosis
(da Cruz et al., 2013) and autoimmune diseases, including
celiac disease (Boniotto et al., 2005), systemic lupus
erythematosus (Lee et al., 2005), Sjögren’s syndrome
(Tsutsumi et al., 2001), and autoimmune thyroid disease
(AITD) (Bevilacqua Filho et al., 2012).
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Table 5 - Analyses of combined alleles of PTPN22 and CTLA4 genes, haplotypes and genotypes of -550 and -221 promoter region and exon 1 of MBL2
gene in TS patients and controls.
PTPN22 CTLA4 Frequencies in TS Frequencies in controls p-value OR (95% C.I.)
G A 0.6512 0.5697 Reference 1.00
G G 0.3372 0.3939 0.16 0.76 (0.52-1.11)
A A 0.0116 0.027 0.25 0.39 (0.08 - 1.93)
A G 0 0.0093 1 0.00 (-Inf - Inf)
Global haplotype association p-value: 0.14
MBL producers and haplotype Frequencies in TS Frequencies in controls p-value OR (95% C.I.)
High MBL producers
LYA 0.3827 0.4272 Reference 1.00
HYA 0.2586 0.2694 0.89 1.04 (0.62 1.73)
Low MBL producers
LXA 0.1453 0.1467 0.69 1.12 (0.64 1.94)
Deficient MBL producers
LYO 0.1464 0.0861 0.13 1.75 (0.85 3.60)
HYO 0.0669 0.0706 0.84 1.10 (0.45 2.67)
Global haplotype association p-value: 0.63
MBL producers and genotypes TS group (n = 65) Control (n = 150) p-value OR (95%C.I.)
High MBL producers
HYA/HYA
HYA/LYA 27 (0.42) 76 (0.51) Reference Reference
LYA/LYA
Low MBL producers
LXA/LXA
LYA/LXA
HYA/LXA
HYA/HYO 32 (0.49) 63 (0.42) 0.278 1.42(0.74-2.76)
HYA/LYO
LYA/LYO
Deficient MBL producers
HYO/LXA
HYO/LYO
LYO/LXA 6 (0.09) 11 (0.07) 0.558 1.53(0.42-5.06)
LYO/LYO
HYO/HYO
Polymorphisms at exon 1 and the promotor region of
MBL2 were evaluated in our study due to their role in innate
immunity and modulation of the inflammatory response. A
relationship between clinical parameters and this genetic
variant has not been assessed previously in TS, making our
study the first to be performed in women with TS.
No association was found between the MBL2 -221
(X/Y allele) polymorphism and different clinical conditions
in TS patients. This MBL2 promoter variation has a signifi-
cant down-regulating effect on the serum MBL concentra-
tion, leading to ineffective clearance of apoptotic cells and
the spread of self-antigens, permitting an immune response
toward autoimmunity and tissue damage (Bouwman et al.,
2006; Araujo et al., 2009). The Y variant is associated with
high serum MBL expression (Madsen et al., 1995) and has
been involved in susceptibility to the development of dif-
ferent diseases (Lee et al., 2005; da Cruz et al., 2013).
On the other hand, our results revealed significant dif-
ferences regarding the -550 (H/L allele) promoter polymor-
phism between TS patients and controls (p < 0.05),
revealing a different distribution in both groups.
Notably, in our study population, the -550 H/L MBL2
variant was not in HWE, though the power analysis ex-
cluded type I and II statistical error. Therefore, we suggest
that the TS condition acts upon the allelic distribution,
causing deviation from HWE. Although differences in the
MBL2 polymorphism distribution have been detected, no
significant association was found regarding the MBL2 -550
(H/L allele) variant and clinical data of the TS group.
In summary, even though our study is a pilot study,
due to limited number of TS patients and controls included,
our results indicate a differential distribution for some
polymorphisms within key inflammation-regulating genes
in TS patients. The understanding of how key immune
genes and its variants are related in TS might help in future
therapy strategies. These findings may open up a new po-
tential line of research to improve life’s quality in these in-
dividuals.
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